SCHEMBL6701121

SCHEMBL6701121

c1ccc(CN[C@H]2CC[C@H](c3ccc(OCc4ccccc4)cn3)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.46
CYP2C9 P11712 1/20 0.46
HRH3 Q9Y5N1 1/20 0.46
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
PRMT5 O14744 1/20 0.45
BCHE P06276 2/20 0.44
FOXM1 Q08050 1/20 0.44
RAB9A P51151 1/20 0.43
GRIN2B Q13224 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
P4HTM Q9NXG6 1/20 0.43
KDM4E B2RXH2 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPK1 P28482 1/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6268294 1.00 KDM1A (0.46) KDM1ACYP2C9HRH3KMT2AMEN1
SCHEMBL6268288 1.00 KDM1A (0.46) KDM1ACYP2C9HRH3KMT2AMEN1
SCHEMBL20754970 0.88 L3MBTL1 (0.54) HRH3KMT2AMEN1L3MBTL1PRMT5
SCHEMBL6716983 0.86 KMT2A (0.46) KDM1AHRH3KMT2AMEN1L3MBTL1
SCHEMBL6716995 0.86 KMT2A (0.46) KDM1AHRH3KMT2AMEN1L3MBTL1
SCHEMBL5555860 0.82 BCHE (0.65) KDM1AKMT2AMEN1BCHEFOXM1
SCHEMBL32677549 0.82 CYP2C9 (0.64) KDM1ACYP2C9HRH3KMT2AMEN1
SCHEMBL6697010 0.78 KDM1A (0.48) KDM1AMAOAMAOBP4HTM
SCHEMBL6697006 0.78 KDM1A (0.48) KDM1AMAOAMAOBP4HTM
SCHEMBL6255935 0.78 P4HTM (0.49) HRH3KMT2AMEN1L3MBTL1PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152715-A1 Cycloalkylene amide compounds as NR2B receptor antagonists KAWAI MAKOTO (JP) 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152715-A1 Cycloalkylene amide compounds as NR2B receptor antagonists GRIN1, GRIN3A, GRIN2A KDM1A 855/4885CYP2C9 2039/4885HRH3 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.